Welcome to CDC Stacks | Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia - 35555 | Emerging Infectious Diseases
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia
Filetype[PDF - 904.33 KB]


Details:
No Related Documents.
You May Also Like:
  1. Nationwide Trends in Bacterial Meningitis before the Introduction of 13-Valent Pneumococcal Conjugate Vaccine—Burkina Faso, 2011–2013
    Personal Author:
    Kambiré, Dinanibè; Soeters, Heidi M.; Ouédraogo-Traoré, Rasmata; Medah, Isaïe; Sangare, Lassana; Yaméogo, Issaka; Sawadogo, Guetawendé; Ouédraogo, Abdoul-Salam; Hema-Ouangraoua, Soumeya; McGee, Lesley; Srinivasan, Velusamy; Aké, Flavien; Congo-Ouédraogo, Malika; Sanou, Soufian; Ba, Absatou Ky; Novak, Ryan T.; Van Beneden, Chris;
    Corporate Author:
    MenAfriNet Consortium
    Published:
    Nov 10 2016
    Source:
    PLoS One. 11(11).
    Description:
    Background : Following introduction of Haemophilus influenzae type b vaccine in 2006 and serogroup A meningococcal conjugate vaccine in 2010, Streptococcus pneumoniae (Sp) became the leading cause of bacterial meningitis in Burkina Faso. We describe ...
    File Type:
    Filetype[PDF - 1.78 MB]
  2. Prevention of pneumococcal disease among infants and children; use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine : recommendations of the Advisory Committee on Immunization Practices (ACIP)
    Personal Author:
    Nuorti, J. Pekka.; Whitney, Cynthia G.;
    Corporate Author:
    United States, Advisory Committee on Immunization Practices.; Centers for Disease Control and Prevention (U.S.); National Center for Immunization and Respiratory Diseases (U.S.), Division of Bacterial Diseases.;
    Published:
    December 10, 2010
    Series:
    MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports ; v. 59, no. RR-11
    Description:
    "On February 24, 2010, a 13-valent pneumococcal polysaccharide-protein conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals Inc., marketed by Pfizer Inc.]) was licensed by the Food and Drug Administration (FDA) for prevention of invasive pneum...
    File Type:
    Filetype[PDF - 569.96 KB]
  3. Pneumococcal Carriage in Young Children One Year after Introduction of the 13-Valent Conjugate Vaccine in Italy
    Personal Author:
    Camilli, Romina; Daprai, Laura; Cavrini, Francesca; Lombardo, Donatella; D’Ambrosio, Fabio; Del Grosso, Maria; Vescio, Maria Fenicia; Landini, Maria Paola; Pascucci, Maria Grazia; Torresani, Erminio; Garlaschi, Maria Laura; Sambri, Vittorio; Pantosti, Annalisa;
    Published:
    Oct 04 2013
    Source:
    PLoS One. 2013; 8(10).
    Description:
    Background : In mid 2010, the 7-valent pneumococcal conjugate vaccine (PCV7) was replaced by the 13-valent conjugate vaccine (PCV13) for childhood immunization in Italy. Our objective in this study was to obtain a snapshot of pneumococcal carriage fr...
    File Type:
    Filetype[PDF - 658.52 KB]
  4. Pneumococcal carriage and antibiotic susceptibility patterns from two cross-sectional colonization surveys among children aged <5 years prior to the introduction of 10-valent pneumococcal conjugate vaccine — Kenya, 2009–2010
    Personal Author:
    Kobayashi, Miwako; Conklin, Laura M.; Bigogo, Godfrey; Jagero, Geofrey; Hampton, Lee; Fleming-Dutra, Katherine E.; Junghae, Muthoni; Carvalho, Maria da Gloria; Pimenta, Fabiana; Beall, Bernard; Taylor, Thomas; Laserson, Kayla F.; Vulule, John; Van Beneden, Chris; Kim, Lindsay; Feikin, Daniel R.; Whitney, Cynthia G.; Breiman, Robert F.;
    Published:
    Jan 05 2017
    Source:
    BMC Infect Dis. 17.
    Description:
    Background : Pneumococci are spread by persons with nasopharyngeal colonization, a necessary precursor to invasive disease. Pneumococcal conjugate vaccines can prevent colonization with vaccine serotype strains. In 2011, Kenya became one of the first...
    File Type:
    Filetype[PDF - 687.33 KB]
  5. Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands
    Personal Author:
    Knol, Mirjam J.; Wagenvoort, Gertjan H.J.; Sanders, Elisabeth A.M.; Elberse, Karin; Vlaminckx, Bart J.; de Melker, Hester E.; van der Ende, Arie;
    Published:
    Nov 2015
    Source:
    Emerg Infect Dis. 21(11):2040-2044.
    Description:
    Three years after a 7-valent pneumococcal conjugate vaccine was replaced by a 10-valent pneumococcal conjugate vaccine in the Netherlands, we observed a decrease in incidence of invasive pneumococcal disease caused by Streptococcus pneumoniae serotyp...
    File Type:
    Filetype[PDF - 1.21 MB]